What does this research mean for the field?

Tirzepatide improves BMI and HbA1c without increasing the incidence or progression of diabetic retinopathy in overweight or obese individuals with Type 1 diabetes. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to investigate the impact of tirzepatide on diabetic retinopathy in overweight/obese individuals with type 1 diabetes.

June 10, 2026Diabetes

1293-OR: Changes in Diabetic Retinopathy (DR) in People with Type 1 Diabetes Using Tirzepatide for >1 Year

View Full Paper

Ask AI

Bookmark

This research aims to investigate the impact of tirzepatide on diabetic retinopathy in overweight/obese individuals with type 1 diabetes.
Retrospective chart review of overweight/obese individuals with type 1 diabetes using tirzepatide for 12 ± 2 months.
Matched cases and controls based on sex, age, and BMI to evaluate diabetic retinopathy changes.
Calculated incidence rates of diabetic retinopathy and analyzed regression/progression for pre-existing cases.
Out of 39 cases without baseline diabetic retinopathy, 10 (25.6%) developed it compared to 7 (29.2%) controls, p=0.78.
Among cases with a significant HbA1c decline of ≥0.5%, 7 (17.9%) developed diabetic retinopathy versus 3 (7.7%) without it, p=0.18.
Most individuals with existing diabetic retinopathy showed stability or regression, indicating no worsening from tirzepatide use.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective analysis observes diabetes-related eye changes in type 1 diabetes individuals using tirzepatide, indicating no adverse outcomes.

Cite This Study

Polsky et al. (2026) studied this question.

synapsesocial.com/papers/6a29012e6f82f25be989d8e7 https://doi.org/10.2337/db26-1293-or

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis observes diabetes-related eye changes in type 1 diabetes individuals using tirzepatide, indicating no adverse outcomes.

1293-OR: Changes in Diabetic Retinopathy (DR) in People with Type 1 Diabetes Using Tirzepatide for >1 Year

Key Points

Discussion

Implication

Cite This Study

1293-OR: Changes in Diabetic Retinopathy (DR) in People with Type 1 Diabetes Using Tirzepatide for >1 Year

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider